NexImmune, Inc. (NEXI)

Verve Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	10.62	13.13	16.31	15.8	10.28	5.98
Research & Development	6.44	16.05	46.77	37.46	17.57	14.9
Operating Expenses	17.06	29.18	63.08	53.26	27.85	20.89
Operating Income	-17.06	-29.18	-63.08	-53.26	-27.85	-20.89
Interest Expense	-	-	-	-0.91	-1.68	-0.01
Interest & Investment Income	0.25	0.7	0.66	0.05	0.02	0.25
Other Non Operating Income (Expenses)	0.77	0.03	-0.09	2.36	-0.35	0.09
EBT Excluding Unusual Items	-16.05	-28.45	-62.51	-51.75	-29.87	-20.55
Merger & Restructuring Charges	-3.1	-3.1	-	-	-	-
Gain (Loss) on Sale of Assets	-1.37	-0.69	-	-	-	-
Asset Writedown	-0.1	-0.1	-	-	-	-
Other Unusual Items	-	-	-	0.84	-	-
Pretax Income	-20.62	-32.34	-62.51	-50.9	-29.87	-20.55
Net Income	-20.62	-32.34	-62.51	-50.9	-29.87	-20.55
Preferred Dividends & Other Adjustments	-	-	-	0.38	3.28	2.66
Net Income to Common	-20.62	-32.34	-62.51	-51.28	-33.15	-23.21
Shares Outstanding (Basic)	1	1	1	1	0	0
Shares Outstanding (Diluted)	1	1	1	1	0	0
Shares Change (YoY)	15.46%	9.05%	19.19%	1508.68%	1.16%	10.53%
EPS (Basic)	-17.39	-30.82	-64.95	-63.51	-660.39	-467.70
EPS (Diluted)	-17.39	-30.82	-64.95	-63.51	-660.39	-467.70
Free Cash Flow	-17.61	-31.48	-52.45	-48.14	-27.27	-20.66
Free Cash Flow Per Share	-14.85	-30.00	-54.50	-59.62	-543.29	-416.40
EBITDA	-16.38	-28.16	-62.09	-52.39	-27.23	-20.45
D&A For EBITDA	0.68	1.02	0.99	0.87	0.62	0.44
EBIT	-17.06	-29.18	-63.08	-53.26	-27.85	-20.89

Updated Aug 7, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.